MedWatch

GN Hearing restructures after research and development letdown

The year of 2021 was meant to bring two new product launches from hearing aid manufacturer GN Hearing, but its research and development division hasn't delivered. Subsequently, the company has dismissed its head of R&D and downgraded its guidances markedly, says CEO at GN Hearing.

Gitte Aabo, CEO at GN Hearing | Photo: GN Hearing / PR

When employees can't deliver as promised, actions must be taken.

That seems to be the reasoning behind CEO at GN Hearing Gitte Aabo's decision to reorganize the company's research and development activities.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Sanofi reduces US insulin prices for the uninsured

While bills to introduce a price cap on insulin are being discussed in the US Senate, Sanofi has beaten them to the punch and reduced the price of insulin products for US diabetes patients without insurance.

Further reading

Related articles

Latest news

See all jobs